Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biopharmagen Corp. Fangzhou Suzhou has 1 pending office action in Biotechnology & Pharmaceuticals. The action involves 1 distinct examiner and 1 distinct art unit, concentrating the identified prosecution activity in one examination setting.
HILL, MYRON G is the busiest examiner, with 1 pending matter. Counsel should tailor the response to the scientific disclosure, claim scope, and cited art presented in the action. The profile does not identify additional examiners or art units requiring a broader coordination strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, MYRON G | 1 | 66.1% | +20.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835420 | BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF | HILL, MYRON G | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835420 | BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF | HILL, MYRON G | 1671 | §112 | Non-Final OA | — | Pending | Aug 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiopharmagen Corp. Fangzhou Suzhou has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Myron G Hill has the most, with 1 of Biopharmagen Corp. Fangzhou Suzhou's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
